Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio includes treatments for cardiovascular, oncology, hematology, immunology, and fibrotic diseases.
Bristol-Myers Squibb Company operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BMY.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BMY Stock Intelligence Report. [stoxpulse.com/stocks/bmy]
Disclaimer: The information on this page about Bristol-Myers Squibb Company (BMY) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Bristol-Myers Squibb Company.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 27%
Jun 30
Short bought 1K shares
4d ago
Short sold 633 shares
4d ago
Why Bristol Myers Squibb (BMY) Dipped More Than Br...
8h ago
Sector Update: Healthcare Stocks Decline Late Afte...
10h ago
StoxPulse AI results for BMY: Pulse Score 50/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$136.49B
P/E Ratio
15.6
EPS
$0.53
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sep 25
+6.9%
Dec 25
+11.9%
Mar 26
+10.4%
Jun 26
+27.2%
Beat estimates 4 of 4 quarters (100%)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Its portfolio includes treatments for cardiovascular, oncology, hematology, immunology, and fibrotic diseases.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Sector Update: Healthcare Stocks Decline Late Afternoon
Sector Update: Healthcare Stocks Decline Friday Afternoon
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?